Showing results (481-490 of 523) with videos related to

Sort By:
Pageof 53
The Lancet. Oncology|April 30, 2026
Clinical trial endpoints for metastases-directed therapy in oligometastatic cancer: a review and Delphi consensus on behalf of the EORTC-ESTRO OligoCare consortiumJoachim Widder, Guus M Bol, Inga-Malin Simek, et al.
Journal of Experimental & Clinical Cancer Research : CR|December 7, 2023
Immune checkpoints are predominantly co-expressed by clonally expanded CD4+FoxP3+ intratumoral T-cells in primary human cancersDelphine Bredel, Edi Tihic, Séverine Mouraud, et al.
The New England Journal of Medicine|January 10, 2024
Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung CancerAlexander Drilon, D Ross Camidge, Jessica J Lin, et al.
Nature Genetics|September 8, 2015
SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomasFrancois Le Loarer, Sarah Watson, Gaelle Pierron, et al.
The Lancet. Haematology|December 12, 2018
Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational studyNicolas Delanoy, Jean-Marie Michot, Thibault Comont, et al.
Lung Cancer (Amsterdam, Netherlands)|October 23, 2020
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatmentVivek Subbiah, Luis Paz-Ares, Benjamin Besse, et al.
The European Respiratory Journal|September 29, 2018
Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trialGuy Meyer, Benjamin Besse, Hélène Doubre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2025
Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2Pascale Tomasini, Yongsheng Wang, Yongsheng Li, et al.
Critical Reviews in Oncology/Hematology|July 11, 2020
Recommendations for detection, prioritization, and treatment of thoracic oncology patients during the COVID-19 pandemic: the THOCOoP cooperative groupOscar Arrieta, Andrés F Cardona, Luis Lara-Mejía, et al.
European Journal of Cancer (Oxford, England : 1990)|May 22, 2021
Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamicsLaura Mezquita, Isabel Preeshagul, Edouard Auclin, et al.
Pageof 53